Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.75 |
| ▸ | HTR3A | P46098 | 1/20 | 0.64 |
| ▸ | JAK3 | P52333 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122 | 1.00 | SLC18A3 (0.75) | SLC18A3SIGMAR1HTR3AJAK3 | |
| SCHEMBL495695 | 1.00 | SLC18A3 (0.75) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL4573453 | 0.98 | SLC18A3 (0.72) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL2173028 | 0.98 | SLC18A3 (0.72) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL2175594 | 0.98 | SLC18A3 (0.72) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL30098419 | 0.98 | SLC18A3 (0.72) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Methylene Chloride SCHEMBL28313080 | 0.92 | SLC18A3 (0.64) | SLC18A3SIGMAR1HTR3AJAK3 | |
| SCHEMBL28296851 | 0.90 | SLC18A3 (0.62) | SLC18A3SIGMAR1HTR3AJAK3 | |
| SCHEMBL28298515 | 0.90 | SLC18A3 (0.62) | SLC18A3SIGMAR1HTR3AJAK3 | |
| SCHEMBL28298504 | 0.90 | SLC18A3 (0.62) | SLC18A3SIGMAR1HTR3AJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| CN-122059950-A | Compounds with proteasome agonistic activity, preparation method and application thereof | 浙大城市学院 | 2026-05-19 | — | — | CN | disclosed |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| WO-2025051829-A1 | NEW PROP-2-YNAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-03-13 | — | — | WO | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118804917-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4442695-A2 | 19-HOMO, 3.ALPHA.-HYDROXY-STEROID-20-ONE COMPOUNDS FOR TREATING CNS DISORDERS | Sage Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | VTV THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007089857-A2 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-1597256-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2004074283-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-5140040-A | Alpha-2-adrenergic receptor antagonist; glaucoma; congestive heart failure; hypotensive agents; headaches; metabolic disorders (diabetes, obesity) | ABBOTT LABORATORIES (US) | 1992-08-18 | — | — | US | disclosed |
| US-5128362-A | Antidepressant, antiglaucoma | ABBOTT LABORATORIES (US) | 1992-07-07 | — | — | US | disclosed |
| US-5086074-A | Selective adrenergic receptor antagonists | ABBOTT LABORATORIES (US) | 1992-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | SLC18A3 1555/4885SIGMAR1 1264/4885HTR3A 29/4885 |
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | PTP4A1, PTPRJ, PTP4A2 | SLC18A3 4133/4885SIGMAR1 4460/4885HTR3A 3725/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | SLC18A3 4867/4885SIGMAR1 2960/4885HTR3A 4140/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | SLC18A3 4801/4885SIGMAR1 4596/4885HTR3A 4363/4885 |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | CCNI, MKI67, TK1 | SLC18A3 3778/4885SIGMAR1 4045/4885HTR3A 3565/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | SLC18A3 1274/4885SIGMAR1 2716/4885HTR3A 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.